Related Experiment Video

Updated: Oct 3, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Treatment and prevention of respiratory syncytial virus infection

M C Kneyber1, H A Moll, R de Groot

  • 1Department of Paediatrics, Sophia Children's Hospital Rotterdam, The Netherlands.

European Journal of Pediatrics
|June 27, 2000
PubMed

Insights

Currently, no effective treatment exists for respiratory syncytial virus (RSV) infections in children. While promising vaccines and passive immunotherapies are under development, further trials and cost-benefit analyses are needed for widespread implementation.

Area of Science:

  • Pediatric Infectious Diseases
  • Virology
  • Immunology

Background:

  • Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract infections in children globally.
  • Current therapeutic options for RSV infections are limited, with no universally effective treatment available.

Purpose of the Study:

  • To review the current knowledge on the treatment and prevention of RSV infections in children.
  • To identify gaps in current therapeutic strategies and highlight areas for future research and development.

Main Methods:

  • Comprehensive literature review of studies on RSV treatment and prevention.
  • Analysis of the efficacy of various pharmacological interventions, including corticosteroids, bronchodilators, ribavirin, vitamin A, interferon, and antibiotics.
  • Evaluation of vaccine candidates and passive protection strategies, such as monoclonal antibodies and immune globulins.

Main Results:

  • Existing therapies like corticosteroids and bronchodilators lack adequate efficacy data. Ribavirin is reserved for specific high-risk immunodeficient patients.
  • Vitamin A, interferon, and antibiotics have shown disappointing results.
  • Vaccine research has yielded candidates (e.g., BBG2Na, PFP-2), but large-scale efficacy trials in infants and the elderly are pending.
  • Passive protection with RSV hyperimmune globulin or palivizumab is costly and may face challenges due to regional prevalence variations.

Conclusions:

  • The development of effective RSV therapies and preventative strategies remains a critical unmet need.
  • Further research is required to establish the efficacy of candidate vaccines and passive immunotherapies.
  • Local and regional guidelines for RSV management should be developed, considering hospitalization rates in high-risk infants and conducting cost-benefit analyses.
Abstract

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Concept Videos

Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...